VANCOUVER, BC, April 27, 2026 (GLOBE NEWSWIRE) — VVT Med Inc. (TSXV: VVTM) (“VVT Med” or the “Company”), a frontrunner in next-generation, minimally invasive, non-thermal, and non-tumescent (“NT-NT”) options for venous illness, is happy to announce that it has entered into its largest European distribution settlement thus far, a strategic unique distribution partnership with Uber Ros S.p.A. (“Uber Ros”) for the commercialization of its ScleroSafe® system in Italy, Vatican Metropolis and the Republic of San Marino (the “Territory”).
Beneath the phrases of the settlement, signed on April ninth, 2026, Uber Ros will function the Firm’s unique distributor within the Territory. The five-year settlement represents roughly CAD $2.3 million in potential income to the Firm, based mostly on agreed minimal buy commitments, with a portion structured below a pay-or-buy mechanism that gives an outlined degree of economic dedication from the distributor, topic to the phrases of the settlement.
Italy is a big and strategically vital healthcare market, with a well-established community of vascular and phlebology specialists. The partnership with Uber Ros allows VVT Med to entry this market by way of an skilled and dedicated native industrial associate, supporting doctor training and product adoption throughout the Territory.
ScleroSafe® is FDA-cleared and CE-marked, enabling its deployment throughout the European Union’s regulatory framework. The Firm’s NT-NT know-how addresses the widest vary of vein diameters, enabling physicians to deal with each the medical and aesthetic elements of venous illness by way of a proprietary, simultaneous sclerosant injection and blood aspiration course of, with no anesthesia and no downtime
“We are very excited to begin this journey with VVT Med,” mentioned Giorgio Rosati, Proprietor of Uber Ros S.p.A. “ScleroSafe integrates perfectly with our existing portfolio in the vascular segment and represents a natural extension of our offering to physicians.”
More Read
“I am also particularly pleased that this agreement comes in a very special year for our company, as we celebrate our 40th anniversary. Over the years, Uber Ros has grown into one of the leading medical device distributors in Italy, representing highly prestigious international brands across multiple specialties, including vascular, orthopedics, trauma, spine, maxillofacial, ENT, and neurosurgery.”
“This partnership further strengthens our commitment to bringing innovative and effective solutions to the Italian healthcare system.”
“This agreement marks another important step in executing our strategy to build a focused international distribution network with committed partners,” mentioned Erez Tetro, Chief Govt Officer of VVT Med. “We believe Italy represents a compelling opportunity for ScleroSafe, and this partnership, our largest European agreement to date, reflects the growing commercial traction of our platform and the confidence that experienced regional partners are placing in our technology.”
More Read
Along with the industrial partnership, Uber Ros has joined the Firm’s beforehand introduced non-brokered non-public placement financing (the “Offering”) as an investor, additional aligning industrial execution with strategic funding, topic to customary situations and, the place required, remaining acceptance by the TSX Enterprise Trade. This participation displays the conviction of the Firm’s distribution companions within the long-term worth of VVT Med’s know-how platform.
The Providing stays topic to customary situations and, the place required, remaining acceptance by the TSX Enterprise Trade. There could be no assurance that the total minimal buy commitments will likely be realized or that the non-public placement will likely be accomplished on the phrases described or in any respect.
The settlement has an preliminary non-cancellable time period of three (3) months (the “Initial Term”), throughout which the Firm is required to pay an combination charge of US$37,500 (US$12,500 per 30 days), adopted by computerized quarterly renewals at a charge of US$12,500 per 30 days (US$37,500 per quarter). After the Preliminary Time period the settlement shall mechanically renew for successive quarterly intervals, every consisting of three (3) months and both celebration could terminate the settlement by offering at least thirty days prior written discover.
Arx is an arm’s-length celebration to the Firm. Arx doesn’t presently maintain any securities of VVT Med Inc.
About VVT Med Inc. (VVTM)VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) options for the therapy of vein ailments, beginning with varicose veins. VVT is the one FDA-cleared, standalone firm providing NT-NT varicose vein therapy know-how. VVT’s FDA-cleared and CE-marked catheter-based applied sciences, ScleroSafe® and V-Block™, allow secure, office-based procedures with no anesthesia, no downtime, and minimal ache and uncomfortable side effects. Addressing the widest vary of vein diameters, VVT’s options empower sufferers by treating each the medical and aesthetic elements of vein illness, whereas enabling physicians to ship efficient, environment friendly, and cost-saving therapies by way of proprietary, simultaneous sclerosant injection and blood aspiration. The Firm’s patented know-how portfolio contains 55 patents from 14 patent households throughout 20 nations, offering broad world mental property safety by way of 2038. For extra data, go to www.vvtmed.com.
Neither the TSX Enterprise Trade nor its Regulation Companies Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Trade) accepts duty for the adequacy or accuracy of this launch.
More Read
Contact InformationErez Tetro, Chief Govt Officer+1 (416) 595 2991
